Cagrilintide Dosage Chart: Once-Weekly Titration, Research Protocols, and the Nitty-Gritty Details

If you’ve been following the latest breakthroughs in peptide-based weight loss therapy, you’ve probably come across cagrilintide – a long-acting amylin analogue that’s got researchers in the metabolic field really excited. This article digs deep into the cagrilintide dosage chart based on what we know from published clinical trials up to 2025 – all written from our perspective at Peptides Unleashed to give you an insider’s look at how this research is unfolding.

Cagrilintide is still not FDA approved as of 2025. Everything we’re presenting here comes from actual research protocols – not treatment advice. As an artificial amylin analogue, cagrilintide takes a different approach to weight loss compared to GLP-1 agonists like semaglutide and tirzepatide. It works by targeting completely different mechanisms for weight reduction and metabolic control.

The dosage chart below is based on once a week cagrilintide shots, given subcutaneously – a gradual increase in dose that lasts around 16-20 weeks, and a range of dose levels tested out in phase 1-3 trials. Here at Peptides Unleashed, our mission – led by Dr. Bradley Thomas – is to provide evidence-based peptide education for individuals interested in their health, without ever trying to sell or prescribe peptides.

Quick Cagrilintide Dosage Chart (Once-Weekly Climbing The Dose)

Here’s a quick rundown of the standard titration schedule as seen in the published trial protocols for cagrilintide for weight loss:

The Basic Once-Weekly Titration Schedule:

• Week 1 – 4: 0.25 mg cagrilintide per week
• Week 5 – 8: bump that up to 0.5 mg per week
• Week 9 – 12: now you’re up to 1.0 mg per week
• Week 13 – 16: next step is 1.7 mg per week
• Week 17+ (maintenance): finally settle at 2.4 mg per week

Keep in mind that research has explored even higher doses – up to 4.5 mg per week. But for the most part, when combining it with semaglutide, the max is usually capped at 2.4 mg to keep the side effects in check.

The titration steps are spaced out about every 4 weeks to minimize the stomach side effects like nausea, constipation, and diarrhea. This gradual climb lets the body adapt to the new stuff, and reduces the risk of side effects.

Now, different research protocols might speed up or slow down the escalation based on how well someone is taking it. And just to be clear – any dosing in humans needs to be done with a qualified healthcare provider or an ethics-approved research team. This chart is purely for educational purposes – not for treatment advice.

What’s Cagrilintide? The Science Behind It

Cagrilintide (aka AM833 in the early days) is a synthetic amylin analogue and a dual amylin/calcitonin receptor agonist – currently in development by Novo Nordisk for type 2 diabetes and obesity research. Unlike the pure GLP-1 agonists, this compound takes a different route – targeting distinct pathways that enhance appetite suppression via multiple physiological mechanisms.

The idea is to slow down stomach emptying, trigger satiety signals in the brain via the area postrema and hypothalamus, and also shut down post-meal glucagon release from the pancreas. This all works alongside GLP-1 signaling – not duplicating it – making it a good candidate for combination therapy.

You might remember a key phase 2 trial that came out in The Lancet Diabetes Endocrinol in December 2021 – a multicentre randomised double blind study which tested once-weekly doses from 0.3 to 4.5 mg over 26 weeks in adults with a BMI of 30 kg/m² or higher, or with comorbidities.

As of 2025, cagrilintide is being put through the wringer in large phase 3 programs (REDEFINE and REIMAGINE) – often paired with semaglutide in what’s called a “CagriSema” combo for weight loss and cardiometabolic outcomes. Not to get too complicated, but these trials are still ongoing and cagrilintide isn’t yet commercially available – so any online access will be in the form of research-only materials that have to be handled with care.

What Can Cagrilintide Do For You?

Cagrilintide is an exciting long-acting amylin analog that’s got a lot of potential beyond just weight loss. Its primary benefit lies in helping you manage your weight effectively by curbing your appetite, which leads to a natural decrease in food intake and sustained appetite suppression. This can not only help you drop pounds but also keep the weight off for good.

But that’s not all – beyond weight loss, cagrilintide has also been shown to improve metabolic health. It can support better blood sugar control and glucose regulation, making it a potential tool for managing type 2 diabetes and related metabolic disorders. By targeting both appetite and blood sugar, cagrilintide addresses key aspects of metabolic control that can be tough to manage when it comes to obesity.## One of the most Exciting Developments

One of the most thrilling recent breakthroughs is the use of Cagrilintide in combination therapy, particularly paired with Semaglutide. This pairing plays on their complementary mechanisms, with Cagrilintide encouraging satiety, slowing down gastric emptying, while Semaglutide not only enhances insulin secretion, but also puts the brakes on appetite even further. If you put them together, the result is significantly better weight loss and improved metabolic outcomes than if you were to use one on its own, making it a game-changer for those looking for a comprehensive weight management solution.

As researchers continue to dig deeper into Cagrilintide’s role in appetite suppression, blood sugar regulation, and combination therapy, it’s clear that it has the potential to be a cornerstone in the future of obesity and metabolic health treatment.

Cagrilintide Dosage Chart: Escalation Phases and Ranges

Getting a handle on the Cagrilintide dosage chart is all about breaking titration down into distinct phases – initiation, mid-range therapeutic dosing, full maintenance dose, and finally high-dose monotherapy exploration.

The usually-once-a-week escalation used in weight loss research kicks off at 0.25-0.3 mg, then steps up to 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg over the course of approximately 16-17 weeks. Some phase 2 studies have tested even higher doses up to 4.5 mg per week to get a better idea of where the upper end of the dose-response curve lies and what the side effect profile looks like at maximum dose levels.

All the numbers on the chart are derived from published or publicly registered trial protocols – we’re talking about things like NCT03856047 and the subsequent REDEFINE/REIMAGINE programs – not commercial weight loss clinics or some unregulated sources.

Low-Dose Initiation Phase (0.25-0.6 mg Weekly)

This phase runs from weeks 1-4 (or longer if needed) and focuses on seeing how well participants can tolerate the drug and whether they get any nasty side effects in the stomach. The 0.25-0.3 mg once weekly starting point came from the dose-finding phase 2 trial, where the 0.3 mg arm showed:

• A weight change of about 2-4% from baseline\
• Nausea in about 20-30% of participants\
• Reduced hunger scores by 20-30% on the VAS (Visual Analog Scale)

Some protocols suggest starting off with 0.3-0.6 mg a week to make sure the brain-gut axis has time to get used to the stronger satiety signals. This is where most people first start to notice that their appetite is under control and they’re eating smaller meals.

In research settings, gradual dose escalation is typically put on hold if participants are experiencing moderate to severe GI symptoms that last longer than 7-14 days.

Moderate Dose Phase (1.0-2.4 mg Weekly)

This is the sweet spot for most weight loss protocols, usually spanning weeks 5-17 in clinical trials. At 1.0 mg a week, appetite control starts to become really noticeable, and weekly weight loss tends to pick up speed.

The 1.7-2.4 mg a week range is the most common maintenance goal in phase 3 combination protocols pairing Cagrilintide and Semaglutide for obesity and type 2 diabetes populations.

Stepwise Progression:

• 1.0 mg a week (weeks 9-12)\
• 1.7 mg a week (weeks 13-16)\
• 2.4 mg a week (weeks 17 and beyond)

Dose increases within this range are spaced at 4-week intervals, provided GI symptoms are mild or are resolving. Phase 2 data showed 8-9% total weight loss by week 26 at these moderate doses, with 60-70% of initial GI symptoms resolving at steady state.

High-Dose Monotherapy Phase (Up to 4.5 mg Weekly)

Once-weekly doses up to 4.5 mg have been studied as Cagrilintide monotherapy in non-diabetic adults with obesity over 26 weeks. This controlled dose-finding phase mapped out the upper end of the dose-response curve.

At the 4.5 mg weekly maximum dosage:

• Phase 2 data showed a 10.8% average weight loss (versus 2.5% for the placebo)\
• 88% of participants reported at least one adverse event\
• Nausea incidence reached 70-80%\
• Vomiting occurred in 30-40% of participants

These higher doses are generally not used when Cagrilintide is combined with full-dose GLP-1 agonists, due to the overlap in their emetic pathways. High-dose regimens should remain within the formal trial settings until long-term safety data from ongoing research gives us a clearer picture of what’s safe.

Cagrilintide Dosage in Key Research Settings

Cagrilintide dosing varies depending on whether it’s being used on its own or paired with GLP-1 agonists, and whether the primary goals are weight loss, blood sugar control, or cardiovascular risk reduction. The following sections reference specific trial designs while trying to keep things concise and accessible.These are not templates for home use, just FYI. The dosing needs to be viewed in the context of the specific clinical trial and supervised setting.

Dosage in Weight-Loss Trials (Non-Diabetic Obesity)

You’ll notice that the classic placebo controlled and active controlled dose finding phase 2 trial enrolled overweight and obese adults for a 26 week treatment period, plus a further 6 weeks of follow up. In this trial, cagrilintide was administered once a week starting from a dose of 0.3 mg up to 4.5 mg.

Trial Design in a Nutshell:

• Participants were started on a low dose and increased every 4 weeks\
• The target doses were 1.2, 2.4, or 4.5 mg per week\
• The results showed a body weight reduction of 6-11% across the different treatment groups\
• To no surprise, higher doses resulted in more weight loss, but also higher rates of serious adverse GI events

Weekly injections of cagrilintide for weight loss came out on top of once-daily liraglutide 3mg, thanks to the much greater convenience of giving a weekly injection as opposed to a daily one.

Dosage in Type 2 Diabetes and CagriSema Combination Trials

The idea of combining cagrilintide with semaglutide is being looked at for type 2 diabetes patients. Most of the time the doses seem to end up at around 2.4mg cagrilintide plus 2.4mg semaglutide once a week after a 16 week escalation period.

One trial – a 32 week double-blind placebo controlled phase 2 trial with 90+ adults with type 2 diabetes – compared:

• Semaglutide on its own\
• Cagrilintide on its own\
• The combination of both semaglutide and cagrilintide

Dual-Escalation – Just to Give You an Idea:

• The cagrilintide dose started at 0.25mg and went up to 2.4mg in a series of four steps\
• Meanwhile, the semaglutide dose also escalated (either in parallel or staggered) to get to 2.4mg

Primary outcomes included the change in HbA1c (1.9% reduction in the combination arms) and enhanced weight loss (15.6% at 20 weeks) – with the combination outperforming monotherapy for both blood sugar control and weight management

Dosage in Long-Term Cardiometabolic Outcome Studies

The REDEFINE phase 3 program (which includes the REDEFINE-3 study) is looking at thousands of overweight and obese adults with and without type 2 diabetes over many years – basically the type of thing you might see in future obesity treatment programs.

A Few Key Long-Term Protocol Features:

• The standard approach here is a stepwise escalation of cagrilintide from 0.25 to 2.4mg weekly over 16 weeks\
• After that, participants are taken off the escalation process and stay on the 2.4mg dose\
• The study goes on for a minimum of 4 years\
• The primary endpoint is looking at MACE (major adverse cardiovascular events) and sustained weight loss trajectories

After the initial 16 week escalation, the rest of the study is just about tracking how participants do on the maintenance dose – in terms of adherence, long-term tolerability, stable blood glucose levels, and cardiovascular outcomes.

Combining Cagrilintide with GLP-1 Agonists: The Theory Behind the Dosage Synergy

One of the main reasons cagrilintide is being paired up with GLP-1 agonists is that they complement each other so well. The amylin pathway targets the saturation signals in the stomach and vagus nerve while the GLP-1 pathway basically addresses how incretin effects are triggered by pancreatic beta cells.

Most of the time, CagriSema trials combine 2.4mg cagrilintide with 2.4mg semaglutide once a week after a gradual escalation of dosages. But because the combination has a more pronounced effect on the GI system, the cagrilintide dose gets capped at 2.4mg.

The clinical trial data would suggest average weight loss of over 20% in some CagriSema cohorts – a pretty impressive result, especially when you consider that you get that kind of weight loss with either drug on its own at the same dose.

An Example Combination Titration Schedule (CagriSema-Style)

So, what does a typical titration schedule look like?

Week by Week – Here’s the Dual Titration Pattern:

Weeks 1-4: 0.25mg semaglutide + 0.25mg cagrilintide

Weeks 5-8: 0.5mg + 0.5mg

Weeks 9-12: 1.0mg + 1.0mg

Weeks 13-16: 1.7mg cagrilintide + 1.0-2.4mg semaglutide ( staggered for minimum GI upset)

Week 17+: 2.4mg + 2.4mg (maintenance)

Both injections are given in separate syringes at different injection sites at least 2-3 centimeters apart.Titration Speed & Tolerance

Titration speed is adjusted based on tolerance. Persistent moderate nausea or vomiting can trigger a hold on the medication and a step-down in dosage. In the case of tirzepatide combinations, while we don’t have a lot of documentation on this yet, it’s likely that similar principles to starting off at a low dose and layering in multiple doses would apply – and that will be something to explore further in future research.

None of these combination therapies are FDA approved outside of clinical trials so any dosage decisions really need to be overseen by investigators or the prescribing physician.

Safety, Side Effects & Dose Adjustments

Cagrilintide’s side effect profile looks very similar to GLP-1 drugs – mostly GI issues that are dose dependent and usually pretty transient, especially if you’re escalating the dose more slowly. The dosage chart is actually designed to help reduce adverse events by moving in tiny increments (about 0.25-0.7mg) and allowing several weeks at each level.

Frequently Reported Side Effects by Dose

• Nausea: 40% at low doses to a whopping 80% at high doses
• Vomiting: 10-40% – not pleasant, I’m sure
• Constipation/Diarrhea: 20-50% – these are dose dependent and usually not too bad
• Abdominal Discomfort: this is dose dependent as well
• Injection site reactions: 5-15% – which isn’t too bad, but some people will still experience it

Some important safety considerations to keep in mind include potential gallbladder issues (about 2-4% incidence – similar to GLP-1 class), monitoring of pancreatitis signals via amylase/lipase, and anti-cagrilintide antibodies showing up in more than half of subjects – usually without any loss of efficacy. People with a history of medullary thyroid carcinoma should definitely discuss the risks with their healthcare provider.

When you’re on this medication, clinical monitoring should include tracking your weight every week, keeping symptom logs, quarterly HbA1c and labs for diabetic patients, and keeping an eye on your blood glucose levels and glucose regulation parameters.

Practical Tips for Tolerating Each Dose Step

Lifestyle strategies can really help support your metabolic health and reduce discomfort while you’re escalating the dose. Here are some tips:

Dietary Adjustments

• Eat smaller, more frequent meals\
• Take your time eating\
• Make sure you’re getting enough protein (this might reduce nausea by 30-50%)\
• Avoid those big, high-fat meals that can make delayed gastric emptying worse

Managing GI Symptoms

• Just make sure you’re drinking plenty of water\
• Increase fibre intake if you’re experiencing constipation (especially at doses 1.7mg or higher)\
• If you’re experiencing more than mild nausea that’s sticking around for more than a week or two, you might want to consider pausing the titration process\
• Over the counter ginger or simple antiemetics might help – but always check with your doctor first

Injection Technique

• Rotate injection sites (abdomen, thigh, upper arm)\
• Make sure sites are several centimeters apart if you’re doing multiple injections a week\
• Proper technique can really help reduce local reactions and mean you preserve muscle mass when you’re losing weight.

Treatment Access, Availability, Insurance & Prescribing Considerations

As of 2025, cagrilintide is still an investigational therapy available only for research purposes, and not yet approved by the FDA for clinical use. So if you’re interested in it for weight management or metabolic health, you’ll have to get it through a clinical trial or some kind of research supplier – not through your usual prescription.

The lack of formal approval means that insurance coverage isn’t generally available. Most people in research settings or early access programs are going to have to pay out of pocket for any associated costs. That’s why it’s really important to understand the regulatory landscape and the limitations of insurance coverage – until cagrilintide gets formal approval.

When it comes to prescribing cagrilintide, healthcare providers have to be really careful and do a thorough review of the patient’s medical history, with particular attention to any history of medullary thyroid carcinoma. This is a known risk factor that might mean they can’t use the medication at all. A careful, individualized treatment plan that gradually escalates the dose to minimize adverse events and optimize outcomes is really essential. Regular monitoring for any serious adverse events – like GI symptoms or rare complications – is also key when it comes to responsible administration of cagrilintide.

There are ongoing clinical trials – like the REDEFINE and REIMAGINE studies – that are looking at the safety, efficacy and optimal dosing of cagrilintide for weight management and metabolic health. These studies are also helping to define the maximum dose – with some research protocols testing up to 4.5mg a week.

Looking ahead, cagrilintide does hold real promise as a future obesity treatment, offering a potentially more effective, evidence-based weight loss solution. Until it gets FDA approval though, access will remain limited to research settings – and any use should be guided by qualified healthcare professionals as part of a structured treatment plan.

Using the Cagrilintide Dosage Chart Safely

This chart just summarises what researchers and clinicians have tested in formal trials – it doesn’t constitute a treatment plan for individual use. The difference between research-grade peptide dosing and prescription-grade, regulatory-approved medication dosing is really important to get your head around.

If you’re interested in a medication like cagrilintide for glucose control or appetite suppression, you should talk to your doctor about the FDA approved options (like GLP-1 agonists) while keeping an eye on the latest research through trial registries.This chart should help you out

• Get a better grasp of what the phase 3 results are trying to tell us
• Understand how to read clinical trial registries so you can spot what’s going on
• Start to be a bit more sceptical about what some peptide vendors are selling as fact

For a deeper dive into all things dosing, how to stack safely, and the fundamentals of peptide therapy, grab our free e-book ‘Peptides Unleashed’ and sign up to our newsletter – all with no obligation at all.

Evidence Summary and Future Directions for Cagrilintide Dosage

When a single weekly dose of cagrilintide got ramped up from .25-0.3 mg to 2.4-4.5 mg over several months, the results were pretty striking – a 6-11% drop in body weight. And get this – when combined with semaglutide, the results were even better, with some people shedding 17-20% of their body weight or more, plus seeing a real improvement in blood sugar levels.

There’s still loads of research being done by the REDEFINE and REIMAGINE phase 3 clinical trials to figure out the long-term sweet spot for dosing (around 2.4 mg a week, probably) and to get more data on how people with obesity and type 2 diabetes do with this treatment. These trials will end up producing the data that’s needed to make informed decisions about future treatment guidelines if the regulators give the green light to cagrilintide-based therapies.

When you see an online dosage calculator or some company hawking research-use peptides, take it all with a grain of salt. The half life of cagrilintide is a lot longer than a lot of other hormones out there and the weekly dosing is undeniably super convenient – but we also want to make sure people are thinking about safety and regulations when it comes to this sort of thing.

The team here at Peptides Unleashed is on a mission to give you the straight goods, based on scientific evidence, so you can have a more informed chat with your doctor about peptide therapy. If you follow the research in this rapidly changing field, whether it’s Lancet Diabetes Endocrinol or some new breakthrough in obesity management, understanding the ins and outs of cagrilintide dosing will help you cut through the noise and stay up to speed.